Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235729 · ClinicalTrials.gov registry record · Phase 3
Lofexidine for Inpatient Opiate Detox
A Phase 3 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 3
- Development phase
- 264
- Enrollment target
NCT00235729 is a Phase 3 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 264 participants.
The verdict
NCT00235729, a Phase 3 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 264 participants
- Enrollment target
Study Summary
The main objective of this study is to investigate the effectiveness of lofexidine in reducing withdrawal symptoms among subjects undergoing opiate detoxification. Currently, lofexidine is the most commonly used non-opiate medication for detoxification from opiates in the United Kingdom (UK). There is no non-opiate medication approved by the Food and Drug Administration (FDA) for the same indication in the United States (US). The only medications currently approved by the FDA for opiate detoxification are methadone and buprenorphine. These medications, however, have the potential to be abused. Lofexidine, on the other hand, offers a unique advantage for opiate detoxification because it is not addicting, is easy to use, and has a favorable safety profile.
Interventions
- DRUG Placebo
- DRUG Lofexidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00235729
The ClinicalTrials.gov registry entry for NCT00235729 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00235729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00235729 about?
NCT00235729 is a clinical study titled "Lofexidine for Inpatient Opiate Detox". The main objective of this study is to investigate the effectiveness of lofexidine in reducing withdrawal symptoms among subjects undergoing opiate detoxification. Currently, lofexidine is the most commonly used non-opiate medication for detoxification from opiates in the United Kingdom (UK). There ...
What is the current status of trial NCT00235729?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 264 participants. The study started on 2006-06. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00235729?
The interventions under investigation include: Placebo (DRUG), Lofexidine (DRUG).
Who is sponsoring clinical trial NCT00235729?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.